ASD & Neurology Quadrant Biosciences develops Clarifi Epigenetic diagnostics for autism spectrum disorder and other neurological conditions, presenting a direct upsell path to clinics and hospitals focused on early detection and personalized care.

Concussion & pediatric NIH grant support for saliva-based microRNA concussion tests in children and adolescents signals expansion potential in pediatric sports medicine, school health programs, and neurology practices seeking non-invasive, rapid screening solutions.

FDA EUA leverage The Clarifi COVID-19 test kit previously received FDA EUA, indicating experience with regulatory processes and scalable diagnostic platforms that can be repurposed or expanded to new infectious disease indications or longitudinal health monitoring.

Strategic leadership Recent hires and awards reflect a growth trajectory and credibility with academic and technology communities, creating opportunities to partner on joint research, pilot programs, and clinical validation studies.

Financial ceiling Revenue range and modest funding suggest a mid-market biotech partner profile with potential for multi-year collaboration in diagnostics development, clinical testing services, and deployment agreements with health systems.